Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

NCT05407584 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Interventions

DRUG: Orevogomab+PLD
DRUG: Orevogomab+Paclitaxel

Sponsor

Yonsei University

Collaborators

[object Object]